Movement Alert｜GENSCRIPT B-1K Falls 4.25% in Regular Trading, Selling Pressure Continues After CARVYKTI Sales Disclosure

Market Focus10-15

On October 15, GENSCRIPT B-1K fell 4.25% intraday, trading at HK$34.46, with turnover of HK$163 million.

The latest market-moving development is that the company had recently disclosed its associate Legend Biotech's core product CARVYKTI generated net trade sales of about US$710 million for the quarter ended September 30, but the figure was based on information provided by Janssen and was not independently verified by either Legend Biotech or the company.

Recent market reports indicate that despite the sales update, funds continued to reassess the stock after sharp prior volatility. Earlier in the week, the shares had already seen heavy swings alongside biotech and AIDD-related names, suggesting that the current pullback reflects continued post-disclosure trading rather than a fresh fundamental announcement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment